The promise of menin inhibitors: from approval to triplet regimens

Hematology (United States) · Published 2025-12-05 · DOI 10.1182/hematology.2025000755

Authors being retrieved — see the publisher record. https://doi.org/10.1182/hematology.2025000755

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2025

Related articles

Targeting the Menin–KMT2A Axis in AML: Translating Molecular Insights into Therapeutic Success. · Clinical Lymphoma, Myeloma and Leukemia · 2026 · Cites or is cited by this article
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment · Hematology (United States) · 2025 · Same journal
From treatment to biology and back: managing iron overload in transfused hemoglobinopathies · Hematology (United States) · 2025 · Same journal
What's new in hereditary hemorrhagic telangiectasia? · Hematology (United States) · 2025 · Same journal
Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)? · Hematology (United States) · 2025 · Same journal
The right patient, the right treatment: tailoring sickle cell disease care · Hematology (United States) · 2025 · Same journal
How to approach the high-risk myeloma from induction through relapse? · Hematology (United States) · 2025 · Same journal
Management of iron overload in adult myelodysplastic syndrome · Hematology (United States) · 2025 · Same journal
When sickle cell trait is not just trait: risk of VTE · Hematology (United States) · 2025 · Same journal
Optimizing the “right” patient selection for treatment for sickle cell disease · Hematology (United States) · 2025 · Same journal